The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.

United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.